Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01409031 · ClinicalTrials.gov registry record · Phase 2
Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension
A Phase 2 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01409031 is a Phase 2 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 3 participants.
The verdict
NCT01409031, a Phase 2 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether intravenous sildenafil reduces pulmonary artery pressure and improves oxygenation in near-term and term infants with persistent pulmonary hypertension.
Interventions
- OTHER Placebo
- DRUG Intravenous Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01409031
The ClinicalTrials.gov registry entry for NCT01409031 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01409031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01409031 about?
NCT01409031 is a clinical study titled "Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension". The purpose of this study is to determine whether intravenous sildenafil reduces pulmonary artery pressure and improves oxygenation in near-term and term infants with persistent pulmonary hypertension.
What is the current status of trial NCT01409031?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2011-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01409031?
The interventions under investigation include: Placebo (OTHER), Intravenous Sildenafil (DRUG).
Who is sponsoring clinical trial NCT01409031?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.